Chakravarti, Deepavali
Hu, Baoli
Mao, Xizeng
Rashid, Asif
Li, Jiexi http://orcid.org/0000-0003-1508-5732
Li, Jun
Liao, Wen-ting http://orcid.org/0000-0003-4953-3134
Whitley, Elizabeth M.
Dey, Prasenjit http://orcid.org/0000-0001-6678-503X
Hou, Pingping http://orcid.org/0000-0002-2429-0861
LaBella, Kyle A. http://orcid.org/0000-0002-0473-9262
Chang, Andrew http://orcid.org/0000-0002-3000-7495
Wang, Guocan
Spring, Denise J.
Deng, Pingna
Zhao, Di
Liang, Xin http://orcid.org/0000-0003-0921-6011
Lan, Zhengdao
Lin, Yiyun http://orcid.org/0000-0002-9277-3048
Sarkar, Sharmistha
Terranova, Christopher http://orcid.org/0000-0002-3674-7013
Deribe, Yonathan Lissanu
Blutt, Sarah E.
Okhuysen, Pablo http://orcid.org/0000-0002-1596-3411
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Vilar, Eduardo http://orcid.org/0000-0001-6404-3761
Nielsen, Ole Haagen http://orcid.org/0000-0003-4612-8635
Dupont, Andrew
Younes, Mamoun http://orcid.org/0000-0001-9618-3451
Patel, Kalyani R.
Shroyer, Noah F.
Rai, Kunal
Estes, Mary K. http://orcid.org/0000-0002-4813-4249
Wang, Y. Alan
Bertuch, Alison A.
DePinho, Ronald A. http://orcid.org/0000-0002-5625-577X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K99 CA218891, R01 CA084628)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 10 February 2020
Accepted: 19 August 2020
First Online: 21 September 2020
Competing interests
: R.A.D. is the co-Founder and Director of Tvardi Therapeutics; co-Founder and Advisor of Asylia Therapeutics; and co-Founder and Advisor of Nirogy Therapeutics. The remaining authors declare no competing interests.